Kyorin Pharmaceutical Co (TSE:4569) Moat Score: 5/10 (As of Jul. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4569 Kyorin Pharmaceutical Co Ltd TSE:4569
74 GF Score
Price 円1,170.00
GF Value 円1,583.07
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Kyorin Pharmaceutical Co Moat Score?

Kyorin Pharmaceutical Co TSE:4569 +0.69% 74 Moat Score is 5 as of Jul. 21, 2026. GuruFocus rates TSE:4569 with a GF Score™ of 74/100 and a GF Value™ of 円1,583.07 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 1,028 Drug Manufacturers companies, Kyorin Pharmaceutical Co ranks better than 94.65% on this metric.

Kyorin Pharmaceutical Co has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Kyorin Pharmaceutical Co has Narrow Moat: Kyorin Pharmaceutical has a solid narrow moat due to its valuable patents and R&D capabilities. However, it lacks the global scale and brand dominance necessary for a wide moat classification.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Kyorin Pharmaceutical Co might have Narrow Moat - Solid narrow moat.

Kyorin Pharmaceutical Co  (TSE:4569) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Kyorin Pharmaceutical Co Moat Score Related Terms

TSE:4569 vs ZTS, UTHR: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Kyorin Pharmaceutical Co's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kyorin Pharmaceutical Co Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kyorin Pharmaceutical Co's Moat Score distribution charts can be found below:

* The bar in red indicates where Kyorin Pharmaceutical Co's Moat Score falls into.


TSE:4569
74GF Score
Kyorin Pharmaceutical Co Ltd TSE:4569
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Kyorin Pharmaceutical Co (TSE:4569) has a Moat Score of 5 as of Jul. 21, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Kyorin Pharmaceutical Co ranks #55 out of 1028 companies in the Drug Manufacturers industry, placing it in the top 5.4%.
Is Kyorin Pharmaceutical Co's Moat Score too high?
Kyorin Pharmaceutical Co's current Moat Score is 5. Based on the distribution chart, Kyorin Pharmaceutical Co ranks #55 out of 1028 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Kyorin Pharmaceutical Co has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kyorin Pharmaceutical Co's Moat Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Kyorin Pharmaceutical Co ranks #55 out of 1028 companies for Moat Score. This places Kyorin Pharmaceutical Co in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Kyorin Pharmaceutical Co's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyorin Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Kyorin Pharmaceutical Co (TSE:4569) is currently considered Modestly Undervalued. The stock's GF Value™ is 円1,583.07, compared to a current price of 円1,170.00 — trading 26.1% below its estimated fair value. The current Moat Score is 5. Kyorin Pharmaceutical Co's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Kyorin Pharmaceutical Co (TSE:4569), the current Moat Score is 5 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kyorin Pharmaceutical Co (TSE:4569) Overvalued in 2026?

Based on GuruFocus' analysis, Kyorin Pharmaceutical Co stock appears to be undervalued. The current stock price of 円1,170.00 is trading 26.1% below its estimated GF Value™ of 円1,583.07. GuruFocus considers Kyorin Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for TSE:4569:

  • Moat Score: 5
  • GF Value™: 円1,583.07 vs. price of 円1,170.00 (26.1% below fair value)
  • GF Score™: 74/100 with 6 warning signs

No single metric tells the full story. See the TSE:4569 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kyorin Pharmaceutical Co Business Description

Address 6, Kanda Surugadai 4-chome, Chiyoda-ku, Tokyo, JPN, 101-8311
Kyorin Pharmaceutical Co Ltd is engaged in manufacturing and sale of pharmaceutical products. The company manages its business in two reportable segments namely Pharmaceutical Business and the Consumer Healthcare (Skincare) Business. The Pharmaceutical business focuses on producing and selling ethical drugs, generic drugs and over-the-counter drugs. The Consumer Healthcare (Skincare) Business mainly sells and purchases skincare products. The company's products include Kipres, for treating bronchial asthma and allergic rhinitis; Mucodyne, a mucoregulant; Pentasa, for treating ulcerative colitis and Crohn's disease; and Uritos, for treating overactive bladder. Majority of the company's revenue comes from domestic sales.
74GF Score

Get the complete analysis for TSE:4569

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円1,170.00
Price
円1,583.07
GF Value